OTS - Biomay Cooperates with BioNTech to Supply DNA Template for COVID-19 mRNA Vaccine
2021. May 18. 09:45
Vienna, 18 May, 2021 (APA/OTS) - Biomay, a Vienna based biotech
manufacturer, today announced their partnership with BioNTech SE to
support the supply chain for manufacturing of the Pfizer-BioNTech
COVID-19 mRNA vaccine. Biomay is one of the manufacturers supplying
BioNTech with the DNA template for the in-vitro transcription of
their mRNA active ingredient.
- Picture is available at AP Images (http://www.apimages.com) -
The manufacturing agreement was initiated during the clinical
development phase of the vaccine in Q1/2020. In the meantime,
Biomay has become a formally qualified supplier for BioNTech. The
scope of services includes process and analytical development,
followed by GMP preparation of the cell bank, manufacturing of
circular DNA plasmid and finally preparation of the linear DNA
template.
In 2021, Biomay has produced and delivered multiple batches of
released DNA template and supported the mRNA vaccine production
thanks to this important manufacturing component, and the company
will continue to do so throughout the year.
Hans Huber, Chief Executive Officer of Biomay, is pleased about
Biomay cooperating with BioNTech on this globally essential
project: "Biomay is proud to be making an active contribution to
combating the coronavirus pandemic. Our staff are highly motivated
and fully aware of the major responsibility associated with this
cooperation. We would like to thank BioNTech for their trust in
Biomay´s expertise. We have been able to demonstrate that our
proprietary plasmid manufacturing platform is well suited to supply
the required high quality and large volume of DNA template."
About the Pfizer-BioNTech COVID-19 Vaccine
The Pfizer-BioNTech COVID-19 vaccine, which is based on
BioNTech proprietary mRNA technology, was developed by both
BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder
in the European Union, and the holder of emergency use
authorizations or equivalent in the United States (jointly with
Pfizer), United Kingdom, Canada and other countries in advance of a
planned application for full marketing authorizations in these
countries.
About Biomay
Biomay AG is a biopharmaceutical contract development and
manufacturing organization (CDMO) with an international reach.
Biomay is recognized as a supplier of plasmid DNA (pDNA),
recombinant proteins and mRNA. Biomay´s clients include start-ups,
midsize biotech companies and multinational enterprises,
predominantly from Europe and the US. Beside the manufacturing of
active ingredients and drug products according to standards of Good
Manufacturing Practice (GMP), the company offers process and assay
development as well as manufacturing of microbial cell banks.
Biomay is currently constructing a fully integrated biotech
manufacturing plant in Aspern Seestadt, Vienna. This greenfield
investment will exclusively be dedicated to Biomay´s biotech CDMO
activities. Parallel manufacturing lines will allow Biomay to
increase its capacities by a factor of 10 with respect to batch
scale and bioreactor volumes (rounded up to ~ 1000 L). Biomay will
move to its new facility in December this year, with GMP operations
scheduled to start in Q1/2022.
Contact:
Dr. Christian Gruber / media@biomay.com / +43-7966296-100 /
www.biomay.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.